Litcius/Paper detail

Multicenter, open-label trial to assess the safety and tolerability of drospirenone 4.0 mg over 6 cycles in female adolescents, with a 7-cycle extension phase

Dan Apter, Enrico Colli, Kristina Gemzell‐Danielsson, Klaus Peters

2020Contraception19 citationsDOI

Topics & Concepts

TolerabilityMedicineDrospirenoneOpen labelMulticenter studyInternal medicineAdverse effectPharmacologyRandomized controlled trialReproductive Health and ContraceptionMenstrual Health and DisordersOvarian function and disorders
Multicenter, open-label trial to assess the safety and tolerability of drospirenone 4.0 mg over 6 cycles in female adolescents, with a 7-cycle extension phase | Litcius